



## News Release

### **Cougar Biotechnology to Present at Lazard Capital Markets Fourth Annual Healthcare Conference**

**Los Angeles, CA, November 20, 2007** – Cougar Biotechnology, Inc. (OTCBB: CGRB) today announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will be presenting at the Lazard Capital Markets Fourth Annual Healthcare Conference on Tuesday, November 27, at 10:00 a.m. EST at The New York Palace Hotel in New York City. Mr. Auerbach will provide a company overview and update on the status of Cougar's current clinical development programs.

Interested investors may access a live audio webcast by visiting the Investor Relations section of the Company's Web site at [www.cougarbiotechnology.com](http://www.cougarbiotechnology.com). The presentation will be archived on the Web site and available for 30 days.

#### **About Cougar Biotechnology**

Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme, which is currently being tested in Phase II clinical trials in prostate cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in hematological malignancies and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types.

Further information about Cougar Biotechnology can be found at [www.cougarbiotechnology.com](http://www.cougarbiotechnology.com).

#### **Contacts:**

Cougar Biotechnology, Inc., +1-310-943-8040  
Alan H. Auerbach, Chief Executive Officer and President  
[ahauerbach@cougarbiotechnology.com](mailto:ahauerbach@cougarbiotechnology.com)  
Mariann Ohanesian, Director of Investor Relations  
[mohanesian@cougarbiotechnology.com](mailto:mohanesian@cougarbiotechnology.com)

Russo Partners, LLC  
David Schull, +1-212-845-4271  
[David.schull@russopartnersllc.com](mailto:David.schull@russopartnersllc.com)  
Andreas Marathovouniotis, +1-212-845-4253  
[Andreas.marathis@russopartnersllc.com](mailto:Andreas.marathis@russopartnersllc.com)

###